Home
Conditions
Lymphoma, B-Cell

Clinical trial condition

Lymphoma, B-Cell

Explore clinical trials studying Lymphoma, B-Cell. Study availability and eligibility vary by location and protocol.

504 public trials 140 recruiting studies

Refine in advanced search Browse all conditions

Lymphoma, B-Cell trial results

Not Yet Recruiting

A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas

NCT07316920

Conditions: Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations: Affiliated Hospital of Jiangsu University Zhenjiang, Jiangsu, China

View Trial Details

Not Yet Recruiting

Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)

NCT07166549

Conditions: B Cell Lymphoma, B Cell Malignancies, B-cell Leukemia, +25 more
Locations: University Hospital Basel, Division of Hematology or Medical Oncology Basel, Canton of Basel-City, Switzerland

View Trial Details

Not Yet Recruiting

A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms

NCT07234045

Conditions: Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +16 more
Locations: China Institute of Hematology and Blood Diseases Hospital Tianjin, Tianjin Municipality, China

View Trial Details

Not Yet Recruiting

Exploratory Study on the Efficacy of Zebutinib as Maintenance Therapy Following CAR-T Cell Therapy in Patients With Non-Hodgkin B-Cell Lymphoma

NCT07198373

Conditions: B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma

NCT07168291

Conditions: Burkitt Lymphoma, DNA Virus Infections, Diffuse Large B Cell Lymphoma (DLBCL), +18 more
Locations: First Affiliated Hospital of Xi'an Jiaotong University Xi'an, Shaanxi, China

View Trial Details

Not Yet Recruiting

This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.

NCT07162571

Conditions: Acute Lymphobkastic Leukemia, B Cell Lymphoma, Hemic and Lymphatic Diseases, +9 more
Locations: State Institution Minsk Scientific and Practical Center for Surgery, Transplantology, and Dermatology Minsk, Belarus

View Trial Details

Not Yet Recruiting

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL

NCT05779930

Conditions: Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia, in Relapse, B Cell Leukemia, +22 more
Locations: Nationwide Children's Hospital Columbus, Ohio, United States

View Trial Details

Not Yet Recruiting

A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

NCT07068906

Conditions: B-Cell Non-Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations: China Institute of Hematology and Blood Diseases Hospital Tianjin, China

View Trial Details

Not Yet Recruiting

CD30 CAR-T in the Treatment of CD30 Positive Lymphoma

NCT07048353

Conditions: B Cell Lymphoma, CD30+ Peripheral T-cell Lymphoma, Hemic and Lymphatic Diseases, +9 more
Locations: Tongji Hospital Affiliated to Tongji Medical College of HUST Wuhan, Hubei, China

View Trial Details

Not Yet Recruiting

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )

NCT07032324

Conditions: B-Cell Non-Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations: Second Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou, Zhejiang, China

View Trial Details

Lymphoma, B-Cell

Lymphoma, B-Cell trial results

Related conditions